Live Breaking News & Updates on வாழ்க்கை அறிவியல் முயற்சிகள்
Stay updated with breaking news from வாழ்க்கை அறிவியல் முயற்சிகள். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Tessera Therapeutics is a Cambridge, Massachusetts-based programmable genetics startup founded by Flagship Pioneering. The genetics company raised US$ 230 million in Series B funding from Alaska Permanent Fund Corporation, Altitude Life Science Ventures, and SoftBank Vision Fund 2, and the Qatar Investment Authority (QIA). Tessera Therapeutics was revealed publicly in July 2020 after years being […] ....
In response to the pandemic, we saw quick action and flexibility from: the Canadian Intellectual Property Office (CIPO) - deadlines from March 16 to August 28 were extended until August 31. On December 14, the Trademarks Office began accepting requests for expedited examination of trademark applications associated with medical goods or services related to COVID-19; the Federal Courts - Federal Court (FC) deadlines were suspended until June 29 or July 13, depending on the province, and a number of hearings and patent trials were conducted by Zoom. Federal Court of Appeal (FCA) deadlines continue to be suspended for some appeals, but are being lifted for selected ....
1. COVID-19: CIPO, Federal Courts, Health Canada In response to the pandemic, we saw quick action and flexibility from: the Canadian Intellectual Property Office (CIPO) – deadlines from March 16 to August 28 were extended until August 31. On December 14, the Trademarks Office began accepting requests for expedited examination of trademark applications associated with medical goods or services related to COVID-19; the Federal Courts – Federal Court (FC) deadlines were suspended until June 29 or July 13, depending on the province, and a number of hearings and patent trials were conducted by Zoom. Federal Court of Appeal (FCA) deadlines continue to be suspended for some appeals, but are being lifted for selected files on a weekly basis. The FC held that the 45-day time limit for commencing a s. 6(1) action under the ....
Share: COPENHAGEN, Denmark, Dec. 15, 2020 /PRNewswire/ MinervaX, a privately held Danish biotechnology company developing a novel vaccine against Group B Streptococcus (GBS), announced today that it has raised an upsized EUR 47.4 million Series B financing. The round included new investors Sanofi Ventures, Wellington Partners, Adjuvant Capital, and Industrifonden, along with existing investors Novo Holdings REPAIR Impact Fund, Sunstone Life Science Ventures, and LF Investment. Proceeds will advance the clinical development of MinervaX s novel GBS vaccine through Phase II clinical trials, as well as manufacturing and regulatory preparation for Phase III. Concurrent with the financing, Christopher Gagliardi from Sanofi Ventures, Karl Nägler from Wellington Partners, Kabeer Aziz from Adjuvant Capital and Bita Sehat from Industrifonden will join MinervaX s board of directors. ....